Physician's First Watch Archive

Medical news from NEJM Journal Watch

July 27, 2015

By Kelly Young

Edited by Susan Sadoughi, MD

The FDA has approved alirocumab (Praluent) as an adjunctive therapy to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (e.g., myocardial infarction or …

By the Editors

The FDA has approved a new assay that will detect HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 …

By the Editors

The FDA has proposed including the percent daily value for added sugars to nutrition labels of packaged …

By Kristin J. Kelley

Edited by Susan Sadoughi, MD

Sonidegib (brand name: Odomzo) has been approved for the treatment of locally advanced basal cell carcinoma. It is indicated for adults …

By Kristin J. Kelley

Edited by Susan Sadoughi, MD

The FDA has approved a ombitasvir/paritaprevir/ritonavir tablet (marketed as Technivie) for treating hepatitis C virus genotype 4 in patients without cirrhosis or scarring. The …

By the Editors

NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:

NEJM Clinical Practice Center: Case Record: A 51-year-old …

July 24, 2015

By Amy Orciari Herman

Edited by William E. Chavey, MD, MS

Two classes of inexpensive medications — aromatase inhibitors and bisphosphonates — reduce breast cancer mortality in postmenopausal women with early-stage disease, according to meta-analyses conducted by the Early Breast Cancer Trialists' Collaborative Group and published in the Lancet.

First, researchers analyzed data from randomized trials comparing adjuvant aromatase inhibitors …

By Kelly Young

Edited by William E. Chavey, MD, MS

Chemotherapy given near the end of life doesn't appear to improve patients' quality of life — and might even worsen it in some patients — according to a …

By Cara Adler

Edited by William E. Chavey, MD, MS

More than half of healthcare providers believe patients expect antibiotics during a visit for a viral illness, whereas only about a quarter of consumers actually expect them, according to survey …

Pages